Shaky Biotech Partnerships Haunt Disease Foundations

Disease foundations have recently become significant stakeholders in biotech companies that may hold the keys to curing the various diseases the foundations represent. However, these foundations are finding themselves vulnerable to biotechs that are falling short on contract promises and pulling the plug on some drug trials. Recent changes in the biotech sector, particularly difficulties in raising capital, have resulted in a trend of foundations increasingly funding “later-stage companies” that would normally receive funding from another source but now are in desperate need of foundation support.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail